Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess.

Launched by IRCCS SAN RAFFAELE · Mar 27, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how certain factors affect bone strength in people with acromegaly, a condition caused by too much growth hormone. The researchers want to understand what makes some patients more likely to have weak bones and fractures. This study is currently recruiting participants who have been diagnosed with acromegaly and can attend regular outpatient appointments.

To be eligible for this trial, participants must have a confirmed diagnosis of acromegaly and be able to provide consent to join the study. However, individuals who are pregnant, have certain serious health conditions, or have had recent fractures may not qualify. Those who join can expect to undergo various tests and evaluations to help researchers gather important information about bone health in acromegaly patients. This study aims to improve understanding and treatment of bone health in this group.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • confirmed diagnosis of acromegaly
• • availability to carry out outpatient checks
• • ability to provide informed consent
• Exclusion Criteria:
• • Pregnancy
• • use of glucocorticoids (except those in use for replacement therapy)
• • alcohol abuse
• • exacerbation of chronic disease
• • serious comorbidities (renal or hepatic failure, heart attack, stroke)
• • terminally ill, prolonged immobilization (\>1 week)
• • clinically evident fracture within the previous six months
• • any other cause of secondary osteoporosis within the last five years
• • any prolonged treatment with drugs with documented influence on bone metabolism during the previous 12 months, including treatment with antiresorptive or anabolic compounds for osteoporosis.